Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024

The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%. This latest report states that such robust growth in the ADHD market can be attributed to the launch of efficacious pipeline products with convenient oral formulations or less frequent dosing than currently available products, an increase in treatment rates, and the continued awareness and recognition of ADHD in the adult age group.

Rachel Markwick, Ph.D., GlobalData’s Analyst covering Neurology and Ophthalmology, explains: "Currently, the ADHD market is rife with unmet needs. These include a need for more treatment options, clinically relevant head-to-head comparisons between current marketed and pipeline drugs, improved diagnostic tests, and increased education and recognition of ADHD."

GlobalData expects that the ADHD market would readily open up to both new and existing drugs that address other unmet needs in this space, which include improved diagnostic rates and subsequent patient uptake across the 7MM.

GlobalData’s report "PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024" will include an interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy, and indication-specific drug sales for the 10 year forecast period.